ABSTRACT
The stem cell microenvironment (in vivo known as niche) is a specific space in the bone marrow (BM), which nurses hematopoietic stem cells and regulates their self-renewal and differentiation using extrinsic cues, such as secreted factors. The niche plays a major role in regulating the number of blood cells and also protects stem cells against excessive proliferation. Till date, several possible secreted regulators of HSC function have been reported. Many of these were originally isolated from stromal cells and the cell lines isolated from hematopoietic tissues. These secreted factors act in concert and not only regulate HSC, but also the niche cells. It has also become clear that deregulation of the niche function is a potential cooperating factor during the development of hematological malignancies. An understanding of how the niche participates in HSC maintenance and repair through soluble factors can offer new opportunities for the development of novel therapeutic tools against hematological malignancies.
INTRODUCTION
Hematopoietic stem cells (HSC) reside in the bone marrow proximal to bone marrow stroma cells (BMSC). Many studies have shown that BMSC regulate the behavior of HSC. BMSC are comprised of a variety of different cell populations (fibroblasts, reticular cells, endothelial cells, adipocytes and osteoblasts) that, in concert, support maintenance of HSCs throughout the lifetime of an adult individual. In vitro, it has been confirmed that BMSCs produce a plethora of soluble factors, such as cytokines and growth factors (e.g., IL3, GM-CSF), as well as form physical interactions (e.g., adhesion) with hematopoietic stem and progenitor cells and extracellular matrix (ECM) molecules (1). This complex of the bone marrow microenvironment thus regulates HSC self-renewal and multilineage differentiation (2). The regulatory mechanisms involved depend on a complex interplay of cell-autonomous and cell extrinsic regulatory mechanisms the outlines of which are still to be resolved in detail (3). In vivo studies have extensively documented the concept of the HSC microenvironment, or niche, described as a three-dimensional cellular unit, close to the endosteal region of bone marrow (BM) (4, 5). In this niche, HSC are protected from differentiation and loss of stem cell function possibly by induction of quiescence (6). Since boneforming osteoblasts are critical for maintaining the size of the HSC pool in vivo, it is thought that osteoblasts are critically active in a functional HSC niche (6, 7). However, as alluded to above, the niche represents a heterogeneous cellular unit. Within this unit, other cell types, which include endothelial cells (8), neural cells (9) as well as feedback mechanisms among mature and immature hematopoietic cells (10), also play an important role. This review largely focuses on soluble factors, which integrate the interactions occurring among HSCs and different cell types of the microenvironment.
SECRETED SOLUBLE FACTORS PRODUCED BY THE NICHE
Osteoblasts produce soluble hematopoietic supportive-secreted and cell-associated factors (e.g., chemokines, interleukins, and interferon's) that overlap in their functions and allow HSCs to derive regulatory information from the niche. Functionally similar to the osteoblastic niche, vascular endothelial cells maintain HSCs in vitro (11, 12) and are required for hematopoiesis in vivo (8, 13). Lodgment of HSCs at the endosteal region appears to favor quiescence or dormancy (14), whereas the more central vascular niche serves as a location that allows differentiation and subsequent mobilization to the peripheral circulation (15). The precise primary cells, which are responsible for modulating HSC function within the adult niche, have not been isolated. It has been described that the presence of spindle-shaped Ncadherin+CD45-osteoblastic (SNO) cells may correlate with HSC function (7). Another population of cells has been described to produce a major soluble factor, which keeps HSC in their niches and attracts circulating HSC to the niche: the chemokine SDF-1α (Cxcl12). This chemokine is mainly produced by Cxcl12-abundant reticular (CAR) cells, which can be found at the endosteal surface, but also near vascular endothelial cells in the bone marrow (16).
A third population of cells express high levels of nestin and show potential to differentiate in different mesenchymal lineages (mesenchymal stem cells), suggesting that the activity of HSC and mesenchymal stem cells are regulated in a coordinated fashion (17). The SNO, CAR, and nestin + cells may express additional regulatory components that influence stem cell function, which include cell-cell receptors, soluble and cell surfaceassociated cytokines, and growth factors. All the so far determined and undetermined factors are influenced directly or indirectly by mechanical, systemic (e.g., PTH), and local (e.g., chemokines, BMPs, Angpt1) signals that regulate niche function (18, 19) . In the paragraphs below, we will describe some of these factors and their possible functions of HSC self-renewal and differentiation ( Figure  1 ). Our own studies showed over expression of several modulators of the Wnt signaling pathway. A loss of one of these, secreted frizzled-related protein1 (Sfrp1), in stromal cells increase production of hematopoietic progenitors in co-culture experiments. In mice deficient in Sfrp1, deregulated hemostasis and an increase in the number of quiescent stem cells (LSK: Lin-Il7r-Sca-1+ Kit+) cells was noted, and this was associated with a decrease in the expression level of β-catenin in these cells in vivo. Serial transplantations of wild type HSCs into Sfrp knockout mice showed a decrease of stem cells (Cd34-LSK: Cd34-Lin-IL-7R-Sca-1+ Kit+) and multipotent progenitor cells (MPP: Lin-IL-7R-Sca-1-Kit+), and a functional loss of HSC self-renewal when Sfrp1 is deficient in the microenvironment. These data demonstrated the role of Sfrp1 as a HSC homeostasis-maintaining protein through extrinsic regulation of β-catenin (33) (see also below). In recent years much knowledge has accumulated using mouse knockout and transgenic models. It has been demonstrated that specification of hematopoiesis as well as hematopoietic self-renewal are intimately linked to developmental pathways (Notch, Wnt, Bmp), cell cycle and epigenetic control. The precise relevance of each of the components of these developmental pathways is, however, still to be elucidated. ), as well as cofactors like p53 and Rb strongly affect HSC self-renewal, where Cdkn2 acts as negative regulator and the other factors mentioned as positive regulators of selfrenewal (38) (reviewed by Orford and Scadden). Besides, these drivers of cell cycle and factors involved in chromatin stabilization during cell division also have a great impact on HSC self-renewal. Factors like Ezh2, Mll, and the polycombgroup complex 1 (PcG1) genes Bmi1, Ring1b, and Rae28 are all required for stem cell maintenance as their deletion causes HSC exhaustion (39) (reviewed by Zon). As it turns out, PcG1 regulates proteasome-mediated degradation of the Cdkns and upregulate geminin, a new player in HSC maintenance and self-renewal (40) suggesting a regulatory feedback mechanism between PcG1 and Cdkn signaling.
SECRETED REGULATORS MAINTAINING

Factors involved in HSC self
The niche and HSC quiescence
Although there is progression in understanding the relative significance of the above intrinsic signaling pathways involved in HSC regulation, it is still unresolved how extrinsic signals affect these. Understanding extrinsic signaling is important in predicting the effects of extrinsic manipulation on HSC. One of such manipulation is the attempt of many investigators to ex-vivo expand HSC, or to restore hematopoiesis after hematopoietic damage. Regarding the expansion of HSC, there are currently no known growth factors or consistent conditions that allow a sustained numerical increase of HSC in culture. The major cause of this is the precise mechanisms by which extrinsic signals are coupled to intrinsic signaling are not known in detail.
The factors critically involved in nichedependent HSC quiescence are slowly being uncovered. HSCs expressing the receptor Mpl or the tyrosine kinase Tie2 are quiescent, resistant to apoptosis and comprised within the, so-called, side population of HSC (41, 73). In addition, Mpl+ and Tie2+ HSC were found to be in direct contact with BM osteoblasts. Primitive behavior of Tie2+ HSC has been implicated both in vitro and maintained in vivo in the formation of cobblestone and induction of longterm repopulating activity of HSCs. Furthermore, secretion of the Tie2 ligand Angpt1 and the Mpl ligand TPO in the BM niche enhances the ability of HSCs to become quiescent and induces adhesion to bone, resulting in protection of the HSC compartment from myelosuppressive stress (41, 72, 73).
Ligands of receptor tyrosine kinases and their role in niche
A variety of soluble growth factors which have been shown to enhance the proliferation of HSC have been dubbed early-acting factors (42). These factors include multi-CSF (interleukin 3, Il3), GM-CSF (Gmcsf), FMS-like tyrosine Kinase-3 ligand (FL, Flt3l), stem cell factor (Kit ligand (Kitl) or SCF), erythropoietin (Epo), interleukin-6 (IL6) and thrombopoietin (Thpo/TPO) (43, 44). The effects produced by these growth factors are dependant on their concentration as well as combination of each one of these components (45).
KIT ligand (SCF)
The SCF receptor Kit is expressed by long-term repopulating stem cells (46). SCF is produced by both fibroblastic cells and endothelial cells and is expressed at development sites such as fetal liver and bone marrow (46, 47). The null alleles of stem cell factor and its receptor ckit, (Sl and W), cause embryonic lethality associated with severe anemia, but viable alleles which lack membranebound SCF, or in which point mutations impair c-Kit tyrosine kinase activity, results in the reduced numbers of CFU-s in the bone marrow of mice harboring Sl or W mutant (46). SCF has been shown to increase adhesion and thus may play a large role in ensuring that HSCs remain in the niche (47). A small percentage of HSCs regularly leave the bone marrow to enter circulation and then return to their niche in the bone marrow (48). The concentration gradients of SCF, along with the chemokine SDF-1, allow HSCs to find their way back to the niche (49). Moreover, different concentrations of SCF affect HSC differently, such that high SCF concentrations are required to promote selfrenewal (50). In addition, the involvement of SCF in survival, mobility, and possibly self-renewal of HSCs in culture and in the HSC niche likely reflects its complex relationship with respect to different cell fates of HSCs.
Triggering of Kit by extrinsic SCF leads to phosphorylation of the intracellular domain of Kit, which contains at least eight phosphorylation sites (51). SCF stimulation starts the Ras/Mapk pathway, as well as the Pi3k/Akt pathway. As a single agent, SCF causes prolonged activation of the Ras/Mapk pathway, leading to loss of stem cells (52). Since it is known that SCF synergizes with other cytokines to maintain HSC, it is possible that these, in fact, cut prolonged Mapk activation short. Through binding to Jak2, Kit also activates Stat3 and Stat5, both associated with promotion of self-renewal and cell cycle progression.
FLT3 ligand (FL, FLT3LG)
The 
Macrophage colony stimulating factor (M-CSF)
A third member of the Kit/Flt3 family is Cfsr1, which is triggered by its ligand Csf1 (M-CSF). M-CSF/Csf1 exists as different splice variants and cleavage products and is expressed by fibroblastic cells, including osteoblastic cells as well as endothelial cells as well as several stromal cell lines (61). Mice deficient in Csf1 or its receptor Csf1r show increased numbers hematopoietic progenitors but an almost complete loss of monocytes/macrophages, suggesting that this ligand pair is dispensable for hematopoiesis, but required for myeloid differentiation (61). Indeed, development of osteoclasts requires the presence of M-CSF. Considering that osteoclasts are important cells in bone remodeling (see below), expression of M-CSF may indirectly regulate the niche. Like Kit and Flt3, the Csfr1 has a multiple phosphorylation site, which upon activation with M-CSF directs the already mentioned Jak2/Stat, Ras/Mapk and Pi3k/Akt signaling pathways.
M-CSF is also one of the few factors that are known to be involved directly in hematopoietic specification, together with G-CSF. Elegant recent experiments using sorted granulocyte/monocyte bipotent cells together with single-cell tracking, showed that M-CSF instructs the decision towards a monocytic cell fate (62). Since the niche produces M-CSF, this also means that not only does the niche regulates HSC quiescence, it is also actively involved in regulating hematopoietic cell fate.
Angiopoietins and angiopoietin-like secreted factors
Angiopoietin-1 (Angpt1), a previously reported ligand of Tie2 (63) In murine fetal liver, a CD3+ Dlk1+ population of cells exists which stimulates HSC expansion (66, 67). These cells secreted high levels of two Angpt family members Angptl2 and 3. The Angptls are mainly involved in lipid metabolism as inhibitors of lipoprotein lipase. In combination with Igf2, these Angptls expand HSC (66). In adults, angptl3 is expressed in the niche, mainly by sinusoidal endothelial cells. It was recently shown that activity of the Angptl factors is not restricted to fetal hematopoiesis. In adult Angptl3-deficient mice, HSC show decreased number and quiescence. Moreover, Angptl3-deficient stromal cells show diminished capacity of support HSC in culture (68). These results strongly suggest the involvement of the Angptl secreted factors in HSC maintenance. So far only Ikaros, a transcription factor known to regulate HSC self-renewal (69), was implicated as Angptl3 downstream intermediate (68). Considering these observations, it would be of interest to find out which receptors (and, thus, signaling pathways) are involved in this response and how signals from the niche modulates these pathways.
Thrombopoietin (TPO)
The early acting factor thrombopoietin (Thpo, TPO) was cloned as a factor mainly affecting thrombopoiesis (70). Many of the molecular pathways that mediate TPO action have been explored. Like all other members of the hematopoietic cytokine receptor family, on binding of this hormone to cells, members of the JAK family of kinases are activated. This in turn phosphorylates the TPO receptor, generating docking sites for second messengers that affect multiple signaling pathways (71). TPO produced by osteoblasts in the BM niche has also been reported as an important mediator to maintain quiescence of BM HSCs. A high expression of the TPO receptor MPL in the side population (SP) of HSC revealed the modulation of thrombopoietin on HSC cell cycle progression on the osteoblast surface. This study demonstrated that a single cytokine could theoretically regulate HSC in the presence of postnatal niche cells (72, 73).
TPO-mediated signaling synergistically induces HSC proliferation with other cytokines. TPO acts as survival factor for HSC (74) and as a single factor, supports long-term maintenance HSCs in stroma-dependent Dextertype culture of bone marrow cells (75). The number of megakaryocyte, granulocyte-macrophage erythroid, and multilineage progenitors are significantly reduced in the bone marrow, spleen, and peripheral blood of either TPO (76) or Mpl deficient mice (77). This phenotype could be recovered with the administration of recombinant murine TPO to TPO-deficient mice and control littermate mice. It also significantly increased the absolute number of myeloid, erythroid, and mixed progenitors in bone marrow and spleen. Furthermore, the megakaryocytopoietic activities of other cytokines in cells from animals without a functional TPO or c-mpl gene have been shown both in vitro and in vivo. Thrombopoietin has been shown to tightly regulate HSC cell-cycle progression at the endosteal surface, and either inhibition or stimulation of Mpl/THPO signaling in LT-HSCs showed reciprocal expression of cell cycle regulators (76, 78, 79).
TPO stimulates Ras/Mapk, Pi3k/Akt and Stat signaling in HSC, and is in that respect similar to SCF and FL. However, where Mapk activation leads to sustained Erk phosphorylation, TPO-induced phosphorylation leads to a transient activation (80), one reason to explain that TPO sustains self-renewal and SCF, as a single factor. The TPO receptor MPL is also intimately linked to the adaptor Lnk (81). This adaptor seems to be required for the ability of TPO to sustain HSC through Jak2 (82). In myeloid dysplasia, Lnk missense and deletion have been found which increase Jak2/Stat5 signaling (83) , suggesting that myeloid disease, the niche has diminished capacity to regulate Jak/Stat signaling through secretion of TPO.
Wnt stimulators and Wnt inhibitors
Wnt proteins are secreted by osteoblast cells in the hematopoietic niche and bind to frizzled receptors (Fzd4 and Fzd6) on the surface of HSCs. Signaling through the canonical Wnt pathway is mostly regulated through signals affecting β-catenin degradation (84) (85) (86) . Mice deficient in the canonical Wnt factor Wnt3a die at E12.5 of embryonic gestation. Although Wnt factors are known to be extrinsic regulators in Drosophila, functionality of Wnt3a-/-HSC was not restored in a wild-type environment, suggesting an intrinsic, rather than an extrinsic defect in Wnt3a-deficiency (87) . Deletion of Wnt5a, a major mediator of non-canonical Wnt signaling is also embryonically lethal. Animals with haploinsufficiency develop myeloid leukemia and B cell lymphomas (88) . Although the specific role of the niche was not investigated, it seems likely that secreted Wnt5a is required for maintenance of normal (89) . Interestingly, Wnt5a stimulation of HSC resulted in an increase of -catenin, suggesting that Wnt5a stimulates canonical, rather than non-canonical pathways in HSC.
Beta-catenin is the major regulator of the evolutionary conserved canonical Wnt signaling pathway. Defects in degradation lead to prolonged stabilization of β-catenin levels in HSCs. Prolonged stabilization results to a loss of HSC dormancy, a concomitant loss of HSC function, and a differentiation block (90) . However, loss of both β-and γ-catenin does not seem to have any affect on HSC behavior (35). Thus, for proper HSC function, catenin levels need to be low. This view is also supported by reports showing that deficiency in the upstream catenin kinase Gsk3 or its ubiquitinase Ubc13 causes similar HSC defects as catenin over expression (91, 92) .
The Wnt signaling pathway is not the only pathway that involves HSC. Indeed, modulation of β-catenin also affects niche function. A non-functional β-catenin induces reduced ability to support early HSCs accompanied by a diminished number of osteoblast and reduction in associated growth factor in vivo (93) . Conversely, over expression of β-catenin improves the ability of stromal cells to support HSC maintenance in culture (94) . Both these reports demonstrate that β-catenin plays an important role in the niche for the generation of osteoblasts, as well as for the preservation of early hematopoietic cells in the HSC niche (93) .
The significance of Wnt signaling for HSC numbers and function is highlighted by observations of HSC regulation by different components of this pathway. Inhibition of Wnt/ β-catenin in bone marrow microenvironment created by the osteoblast-specific over expression of Dkk1 resulted in the increase of the number of proliferating HSCs and the reduction in the ability to reconstitute the system of irradiated recipient mice, showing that microenvironment-related Wnt/β-catenin activity is crucial for the maintenance of HSC quiescence (95) . Our own work with Sfrp1 knockout mice revealed diminished HSC self-renewal in the absence of niche Sfrp1. Surprisingly, Sfrp1 deficiency also lowered β-catenin levels in HSC isolated from their niche environment, suggesting that in vivo, Sfrp1 may, in fact, act as a Wnt stimulator. This hypothesis warrants further investigation, since it has been shown that Sfrp1 may directly bind to Fzd receptors, some of which are expressed on HSC, like Fzd4 (89) . Thus, the fine-tuning of Wnt/β-catenin activity might be crucial for the balance between maintenance of HSC quiescence and differentiation (96) .
Notch ligands
Notch signaling plays an important part in both HSC regulation and in osteoblastic cells. Apart from the multiple in vitro studies (97) (98) (99) (100) , evidence for a role of Notch signaling between HSCs and the bone marrow microenvironment in vivo remains ambiguous. Several lines of evidence strongly suggest a role for Notch in the interactions between HSC and the niche. First, the Notch ligand Jagged1 is expressed in BM stromal cells and murine osteoblastic cells and increased Jagged 1 (Jag1) in human stroma is sufficient to expand HSC (97) . Additionally Jag1 is expressed by human-derived CD146+ cells multipotent stromal cells (101) , which can form a hematopoietic supportive niche in vivo (64). In addition, MSC uniquely express Notch3, suggesting possible feedback mechanisms between MSC and cells with which they interact. Although the functionality of Jag1 in these cells was not examined, the observation that HSC and MSC form a niche in vivo (17) further supports the idea that Notch signaling in the niche is important in interaction with HSC.
In contrast to this data, other investigators reported findings which suggest that neither Jagged1 nor Notch signaling are required for maintaining HSC populations. For instance, in mouse studies in which Jag1 was conditionally deleted no differences in basal levels of HSC was noted (102) . Further loss of Notch1 on HSC also did not influence engraftment and HSC self-renewal (102) . One explanation for this finding could be that Jag1-associated Notch signaling is mediated by other signaling elements in this pathway. However, expression of a dominant-negative isoform of mastermind (DNMAML), ruled out the possibility of compensation by alternative Notch receptors, indicating the dispensability of notch signaling for the maintenance of HSC at steady state (34).
However, Notch signaling was shown to be required for megakaryocytic differentiation (103) . HSCsupportive cell lines are characterized by expression of the putative Notch ligand Dlk1 (22, 30). Dlk1 (Pref-1) is an imprinted gene which is also expressed in HSC and its action appears to be to limit proliferation and differentiation (164). Interestingly, studies in Dlk -/-mice suggest that proper B-cell development requires the presence of Dlk1. Whether Dlk1 is a true ligand for the Notch receptors is unknown at present. Inactivation of Mind bomb-1 (Mib1), which is essential for Notch ligand endocytosis and subsequent Notch activation in the microenvironment, results in myeloproliferative disease. These results imply that defective Notch signaling in nonhematopoietic microenvironmental cells can be the cause of the myeloproliferative disease. These experiments also indicate that, although Notch signaling in HSC may be dispensable for normal hematopoiesis, Notch signaling may be required for HSC support in the microenvironment (104).
Secreted Factors involved in stem cell adhesion and lodging
HSC lodge very close to the endosteal surface (105) (106) (107) (108) , indicating that, on the one hand, HSC home very efficiently to the niche, and, on the other hand, the endosteal niche is the preferred environment of HSC. Homing and adhesion depend on a complex of subsequent mechanisms involving rolling, firm adhesion and transendothelial migration. Stromal derived factor-1 (Sdf-1 or Cxcl12) is a chemokine produced by osteoblasts, fibroblasts, and endothelial cells in response to injury. Cxcl12 and its receptor: Cxcr4 are critically involved in chemotaxis of HSC to the bone marrow during development, and their absence cause defective myelopoiesis and B-lymphopoiesis (109) . Moreover, Cxcl12 is a critical factor in guiding the matrix metalloproteinase 9 (Mmp9) dependent transendothelial migration of hematopoietic cells into the bone marrow microenvironment (110) .
Once within the microenvironment, Cxcl12 regulates lodgment of HSC within the endosteal region, where, in collaboration with TGF, it controls the HSC quiescence/cycling switch through Cxcr4 (111, 112 (117) . Other secreted factors may also influence adhesion through so-called inside-out signaling mechanisms that regulate the affinity of adhesive receptors. The most important adhesive receptor is the α4β1 integrin (VLA-4)(118), which binds mainly to its ligand Vcam1 and also to fibronectin (Fn). Adhesive activity of the α5β1 integrin VLA-5 to Fn is inducible (119) . Examples of this kind of regulation are the modulation of the affinity of the integrins, VLA-4 and VLA-5 to their respective ligands Vcam1 and Fn by Il3 (120), Gmcsf and Scf (118, 121) , and Tpo (122) . In addition, different adhesive receptors may cross-talk to regulate affinity of VLA-4 and -5 (119). The interesting aspect of these studies is that the induction of adhesion does not last, but subsides [66] . The significance of this observation is unclear, but opens the possibility that cells move within the niche and are only tightly bound to certain cells in the niche for a limited period of time. These studies show that secreted factors may improve HSC survival in the niche at least in part by modulating their adhesive behavior, and that loss of adhesion may constitute a differentiation-promoting environment.
Tight adhesion of HSC to the niche is almost certainly mediated through signaling through the Rho GTPase Cdc42 that not only regulates adhesion (123) , but also HSC proliferation (124) . In addition, Cdc42 is required for proper B cell development (125) . The niche itself is not a passive adhesive substrate in the process of HSC lodging. Indeed, niche cells defective in annexin 2 (Anxa2) expression fail to support HSC adhesion, and HSC show defective survival in Anxa2-deficient animals (126) . In addition, as noted above, Wnt signaling is of critical importance as an intrinsic determinant in the balance of HSC proliferation and differentiation. There is now also evidence that canonical Wnt signals modulate HSC supportive activity of non-hematopoietic niche cells. Indeed, over expression of β-catenin in stromal cells, significantly improved their ability to support HSC in culture (93, 94) . Since Wnt signaling is required for skeletogenesis (reviewed by Macsai et al (127), and Williams and Insogna (128) this pathway may not only directly regulate HSC, but also, the size of the niche.
Secreted factors that retain stem cell pool and niche size
As described above, niche factors determine the balance between HSC quiescence and cell cycle entry, with subsequent differentiation. Thus, beside the factors that control quiescence, other factors constrain the size of the stem cell pool. Since osteoblasts are important in this process, it was hypothesized that continuous activation of osteoblasts would affect HSC behavior. Indeed, when osteoblasts are activated by parathyroid hormone, many factors are secreted, including Sfrp4, Bmp4, Jag1, TGF and Opn (129, 130). Studies of Opn-deficient mice demonstrated that in the absence of Opn, the number of HSC increases in a stromal cell-dependent manner. This, in turn, is associated with increased stromal Jag1 and Angpt1 expression and a reduction in primitive hematopoietic cell apoptosis. Activating osteoblasts with parathyroid hormone in the absence of Opn induces a strong increase in stem cells, indicating that physiological Opn limits the affects of niche activation on HSC cycling (130) .
Although the size of the niche is relatively poorly researched, one could speculate that secreted factors that affect remodeling of trabecular bone, will also affect niche size. Remodeling of bone is a complex process in which bone is formed by osteoblasts and osteocytes, and also resorped by osteoclasts. Obvious factors responsible in this respect are Wnt3a and its inhibitors Dkk1 and Sfrp1. As described in detail above, all these factors have known affects on HSC self-renewal. Wnt factors not only directly affect HSC but also affect bone remodeling. Both Dkk1 and Wnt3a increase osteoblast proliferation, and where Dkk1 stimulates osteoclast differentiation (131), Sfrp1 has been shown to inhibit Rankl-dependent osteoclast differentiation (132, 133) . Thus, like in regulation of HSC, Dkk1 and Sfrp1 appear to exhibit opposite affects on bone remodeling. Beta catenin itself promotes differentiation of MSC into early osteoblasts (134) . Other mediators that are thought to regulate hematopoietic stem cells at least in part through altered bone remodeling are Serpina1 (135), Timp3 (136) and Ebf2 (137) .
Bone remodeling is also altered during stem cell mobilization. Clearly mobilization protocols using the growth factor G-CSF affect hematopoietic cells. It has been shown that HSC mobilize in part because of the niche remodeling.
During mobilization, Opn-expressing osteoblasts are depleted and once the mobilizing agent is removed, rapid expansion of these cells occur (138). This process primarily depends on tropic endosteal macrophages (139). Thus G-CSF causes HSC proliferation and mobilization by temporary remodeling of the niche.
THE CANCER STEM CELL NICHE
The behavior of cancer stem cells (CSC) resembles that of normal stem cells. Although it has long been thought that cancer stem cells were actively cycling cells, it is now clear that quiescent leukemia stem cells exist (140, 141). Niche cells regulate CSC in much the same way as normal HSC. Nevertheless, the precise role for the niche in cancer development is still a mystery. Some studies show that knocking out the extrinsically-regulated phosphatase Pten, results in mobilization and eventual depletion of normal HSCs with the generation of CSC (142) (143). This observation is associated with an increased HSC mobilization and development of leukemia. In such cases, it is well possible that the CSC niche functions normally in the presence of tumor cells. Tumor cells may already have been selected for secondary mutations that promote their survival. For instance, downregulation of the ubiquitinase Cbl increases expression of survival-and proliferation-promoting receptor tyrosine kinases such as Kit and Flt3. Activating mutations in kinases such as Pim1, which regulates Cxcr4 expression (116) may promote proliferation, and thus, the emergence of additional mutations. Several lines of evidence strongly suggest that intrinsical stromal dysfunction is a cooperating factor in the development of leukemia. Deficiency of the NF-B signaling intermediate Ikba (144), the Notch pathway mediator Mib1 (104) and the cell cycle regulators Rb (145) and Rarg (146) cause a non-cell autonomous myeloproliferation involving deregulation of HSC homing, and alterations in Notch, and Tnf signaling in HSC.
More recent work has elegantly shown that the osteoprogenitor-specific absence of Dicer1 and Sbds causes myelodysplasia with increased hematopoietic cell turnover, which in some animals developed into myeloid sarcomas (147). In all these models, it seems likely that intrinsic changes in the stromal cells lead to altered extrinsic signaling. However, the nature of the changes in these signals have not been explored. Jag1 expression is altered in the Pten -/-, Ikba -/-as well as the Dicer1 -/-mice, suggesting Notch signaling is commonly involved in the hematopoietic deregulation. However, the secreted factors differentially expressed in Dicer-deficient osteoprogenitors do not include known Notch ligands. Thus, stromal dysfunction may collaborate with CSC in the development of leukemia. But, the alterations in secreted factors between the CSC niche and the normal HSC still needs to be elucidated in detail.
Dynamic in vivo imaging show that leukemic cell growth disrupts normal hematopoietic stem cell bone marrow niches and creates abnormal microenvironments that confiscate transplanted human CD34 + (HPC-enriched) cells. CD34 + cells in leukemic mice declined in number over time and failed to mobilize into the peripheral circulation in response to cytokine stimulation. The normal phenotype could be rescued by neutralizing stem cell factor (SCF) secreted by leukemic cells. Thus, CD34
+ cell numbers could be normalized, and their mobilization restored in leukemic mice (148). In experiments with infused childhood ALL cells, it has been noted that the leukemia cells secrete SCF that, in turn may attract the normal HSC. As a result, the CSC forms a new niche, which also harbors normal HSC. However, this CSCinduced niche does not maintain normal hematopoiesis, probably by interfering with a return to quiescence, causing a depletion of normal cells. So far, this is an isolated, but intriguing observation that awaits confirmation in other CSC model systems (149) .
THERAPEUTIC RELEVANCE AND PERSPECTIVES
The former paragraph clearly demonstrates that stromal dysfunction contributes to leukemia development. Furthermore, once the leukemia has developed, the CSC may influence normal niche function. These observations open the possibility of targeting the niche as a novel therapy of leukemia disease. In order to ensure successful translation of this concept, the underlying signaling mechanisms for homing, lodging and transmigration of HSC out of the microenviroenment needs to be addressed more specifically. In particular, the differences between normal HSC and CSC behavior need to be addressed. Some recent model studies have begun mapping the homing, proliferation and survival sites of the human leukemia cells in comparison to normal cord blood CD34+ cells.
A crucial role of both the osteoblastic niche and vascular niche in providing anti-apoptotic signals has been described (150). As mentioned above, secreted factors influence quiescence, cell cycle entry, regeneration, as well as cell survival. The latter is most probably tied into the mechanisms regulating dormancy and likely to involve adhesive mechanisms. The activation achieved with cell-tocell adhesion forces has been shown to be important for the persistence for both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) CSCs (151) (152) (153) . The late survival-signaling cascade is switched on with the ligation of integrins and as a result of the direct contact of leukemic CSC with BMSC downstream anti-apoptotic signaling is activating. The blockade of the adhesion regulator and integrin-linked pseudokinase ILK (154) with a specific inhibitor QLT0267 specifically inhibits the downstream signaling in leukemia cells (155) . Interestingly treatment of normal hematopoietic cells appears refractive to inhibition of ILK, suggesting ILK is not involved normal hemostasis (156) . Another way of disrupting adhesive interactions between leukemia CSC and the niche is by interfering with Cxcl12 signaling. Interfering with lodgment could force cells out of quiescence into cell cycle entry, which would make them susceptible to cytostatic and apoptotic therapy. Cxcr4 levels are significantly elevated in subtypes of leukemia (AML, B-CLL, B-or T-cell ALL) (157) . A possible mediator of Cxcr4 up regulation is the up regulation or activated mutations of Pim1 (158) by activated FLT3 mutations. Since FL is produced by the niche, anti-FL or Pim1 inhibitor treatment are possible modalities by which leukemia may be treated in the future.
Treatment with AMD-3100, a specific antagonist of CXCR4, induces rapid and robust HSC mobilization in both humans and mice (159, 160) . Recently, administration of the Cxcr4 antagonists AMD3100 or the rcp168 peptide in combination with chemotherapy has been shown to trigger the movement of APL CSCs in blood and improve overall survival (161, 162) . Similar observations have been made in the case of primary CLL and AML cells. Role of E-selectin and P-selectin in the HSC homing to the BM has been well characterized in mice using function -blocking antibodies or targeted deletions of these genes. When Eselectin and β1-integrin were inactivated, the deficient recipients revealed a profound alteration in HPC homing (> 90% reduction). Competitive assays to test homing of longterm repopulating stem cells also revealed a drastic reduction (> 99%) of the homed stem cell activity. Further homing studies with PSGL-1-deficient HPCs pre-treated with anti-4 integrin antibody revealed that PSGL-1 contributes to about 60% of E-selectin ligand-mediated homing activity (9).
So far, no therapies exist which specifically target the leukemia niche or molecules deregulated in niche cells that could contribute to leukemogenesis. Considering the myeloproliferation present in mice with deletion of Ikba, Mib1, or Pten, one could envision targeting these molecules to "quiet down" HSC. Also, since cALL cells may secrete SCF which creates a secondary leukemia, niche targeting specific early acting factors like SCF or its receptor: Kit may also be an option. Indeed, anti-SCF restores the normal localization of HSC (148) and enhances chemotoxicity in AML cell lines (163) . Other niche factors known to reinforce HSC dormancy, such as the Wnt inhibitors Sfrp1 and Dkk1, are frequently down regulated in human cancer. Since over expression of Dkk1 decreases HSC self-renewal, Dkk1 agonists could be of help in interfering with self-renewal of leukemia CSC. The delineation of the networks of soluble niche factors involved in regulation of normal self-renewal, cell cycle entry, regeneration and adhesion are incomplete. The same can be said for what is known about the cellular components involved and the feedback mechanisms existing between these cells. Clearly, since disruption of normal niche function interferes with normal HSC regulation and promotes leukemogenesis, the niche is is more and more becoming an attractive target for the therapy of leukemia.
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